[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622121":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":39,"responsibleParty":54,"collaborators":25,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":81,"whyStopped":25,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"CMH Kharian Medical College","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"letrozole","ACTIVE_COMPARATOR","30 participants with PCOs will receive tab letrozole 2.5mg 2 x OD for 5 days",[13],"Drug: Letrozole (Aromatase Inhibitors)",{"label":15,"type":16,"description":17,"interventionNames":18},"letrozole plus estradiol valerate","EXPERIMENTAL","30 participants with PCOs will receive tab letrozole 2.5mg 2 x OD for 5 days plus tab Estradiol valerate 2mg OD for 12 days",[19],"Drug: Letrozole (Aromatase Inhibitors) + Estradiol valerate",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Letrozole (Aromatase Inhibitors)",[9],null,{"type":22,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"Letrozole (Aromatase Inhibitors) + Estradiol valerate",[15],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Maryum Noor Malik, MBBS, FCPS, CHPE","CONTACT","+923111777089","maryam.n.malik24@gmail.com",{"name":36,"role":32,"phone":37,"phoneExt":25,"email":38},"Mushayada Irshad, MBBS, Mphil, CHPE","+923237088421","mishy2360@gmail.com",[40],{"facility":5,"status":25,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":25,"geoPoint":25,"contacts":46},"Khārian","Punjab Province","50070","Pakistan","PK",[47,48,49,51],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},{"name":36,"role":32,"phone":37,"phoneExt":25,"email":38},{"name":31,"role":50,"phone":25,"phoneExt":25,"email":25},"PRINCIPAL_INVESTIGATOR",{"name":52,"role":53,"phone":25,"phoneExt":25,"email":25},"Mugheera Hussain, MBBS, FCPS, MRCPI","SUB_INVESTIGATOR",{"type":50,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Maryum Noor Malik","Senior Registrar Ob\u002FGyn","100622121","endometrial-response-in-polycystic-ovarian-syndrome-treated-with-letrozole-alone-or-with-added-estradiol-valerate-100622121",false,"NCT07379502","Endometrial Response in Polycystic Ovarian Syndrome Treated With Letrozole Alone or With Added Estradiol Valerate","Endometrial Response in Women With Poorly Primed Endometrial Lining in Diagnosed Polycystic Ovarian Syndrome Treated With Letrozole Alone or With Added Estradiol Valerate","Inclusion Criteria:\n\n* Women aged 20-35 years\n* Clinical diagnosis of PCOS (Rotterdam criteria)\n\nExclusion Criteria:\n\n* Endocrine disorders other than PCOS\n* Endometrial pathology or uterine malformations\n* Allergy to letrozole or estradiol\n* Hormonal therapy within last 3 months","FEMALE","20 Years","35 Years",{"count":68,"type":69},60,"ESTIMATED","INTERVENTIONAL",[72],"NA","Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age, characterized by chronic anovulation, hyperandrogenism, and polycystic ovarian morphology. Letrozole, an aromatase inhibitor, has emerged as a first-line ovulation induction agent due to its superior ovulation and pregnancy rates compared to clomiphene citrate. Estradiol valerate, a synthetic estrogen, can be co-administered with letrozole to improve endometrial receptivity by enhancing endometrial thickness, vascularity, and pattern. This study aims to evaluate the effect of letrozole alone versus letrozole with estradiol valerate on endometrial development in these patients.",[75],"PCOS (Polycystic Ovary Syndrome)",[75,77,78,79,80],"Letrozole","Estradiol Valerate","Endometrial response","Endometrial thickness","NOT_YET_RECRUITING","2026-01-27",{"date":84,"type":85},"2026-01-30","ACTUAL",{"date":87,"type":69},"2026-03-05",{"date":89,"type":69},"2026-08-31",{"name":5,"class":6},1]